David R. Bauer

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…

Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by Theravance Biopharma, Inc. Theravance Biopharma’s ordinary shares…

Davis Polk advised the underwriters in connection with a $75 million public offering of common stock by RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on the …

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the…

Davis Polk advised the joint book-running managers in connection with an initial public offering of 10,586,316 shares of common stock of Black Diamond Therapeutics, Inc. In addition,…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $207 million public offering of common stock of Denali Therapeutics,…

Davis Polk advised the underwriters in connection with the SEC-registered offering of 3,152,712 shares of common stock of Applied Therapeutics, Inc., including 411,223 shares of common…

Davis Polk advised the underwriters on the SEC-registered initial public offering by I-Mab of 7,407,400 American depositary shares, each 10 ADSs representing 23 ordinary shares, for total…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $195.6 million public offering of common stock of Forty Seven, …